A trial of Timoptol (timolol maleate) in a clinical situation.
The results of treatment with Timoptol in 138 cases are reviewed. There was an average lowering of pressure by 6mm Hg in the whole group with an average follow up of 10 weeks (range 2-26 weeks). Most patients had a satisfactory fall only when Timoptol was combined with other treatment, with a fall of 3mm Hg or more in 60% of patients and with pressure controlled to less than 22mm Hg in 48 to 55%. A good response was achieved in all types of chronic open angle glaucoma except in low tension glaucoma. In established glaucoma it seems best to add Timoptol to the existing therapy and then modify treatment as indicated. Serious side effects occurred in five patients; 2 with severe pain, 2 with an attack of angle closure glaucoma, one a general sensitivity reaction and one with temporary central visual loss, but these do not detract from the immense potential of the drug in treatment of glaucoma.
D004359:Drug Therapy, Combination; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D011412:Propanolamines / Q000627:therapeutic use*; D013999:Timolol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D011412:Propanolamines; D013999:Timolol